Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 27;23(1):59.
doi: 10.1186/s12969-025-01113-3.

Management of childhood-onset systemic lupus erythematosus (cSLE) over the last two decades in Spain

Alina Boteanu  1 , Juan José Bethencourt  2 , Joan Calzada-Hernández  3 , Daniel Clemente  4 , Juan Carlos Nieto-González  5 , Covadonga López  6 , Laura Luque  7 , Inmaculada Calvo  8
Affiliations
Review

Management of childhood-onset systemic lupus erythematosus (cSLE) over the last two decades in Spain

Alina Boteanu et al. Pediatr Rheumatol Online J. .

Abstract

Background: Childhood-onset systemic lupus erythematosus (cSLE) is a chronic multisystemic autoimmune disease with a more severe and life-threatening course than SLE in adults. Up to 50-80% of patients have renal or other major-organ involvement, such as in the neurological or nephrological systems, which results in significant morbidity and increased mortality.

Main text: A search was conducted for lupus-related literature published by Spanish authors in PubMed, Science Direct, MEDES and SciELO databases. The search strategy was based on the keywords "paediatric OR pediatric AND lupus AND Spain" from 2005 to 2024. A manual search was also performed with the above keywords, including "Clinical practice guidelines OR protocols OR recommendations". Significant changes in the management of cSLE have occurred over the last 20 years in Spain. Since there is no consensus among experts at a national scale, the use of off-label drugs and the insufficiency of evidence-based recommendations have become widespread. Antimalarials and glucocorticoids have remained the cornerstone of treatment for several years. However, the side effects of the latter and their association with the accumulation of organ damage have led to the incorporation of immunosuppressants and biologic agents into clinical practice earlier in the course of the disease as glucocorticoids-sparing strategies. Recent advances in cSLE management include the application of the treat-to-target approach and the approval of intravenous belimumab for patients ≥ 5 years, while early results with subcutaneous belimumab in cSLE have as well demonstrated efficacy and safety.

Conclusion: Despite the initiation of the Spanish Juvenile Systemic Lupus Erythematosus Registry in 2021, which aims to ascertain the outcomes of cSLE in Spanish patients, a consensus document for the management of these patients in Spain remains elusive. According to Treat to Target TaskGroup, treatment of cSLE should aim to ensure long-term survival and prevent organ damage. The use of glucocorticoid-sparing strategies, including biological agents such as belimumab, represents one of the main current challenges. Indeed, subcutaneous belimumab could be a promising tool in cSLE, as its administration in school-aged patients might reduce school absenteeism and lead to an improvement in the child's overall health.

Keywords: Belimumab; Childhood-onset systemic lupus erythematosus; Management; Spain; Therapeutic development.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: AB has received speaker honoraria from Novartis and GSK. JJB has received speaker honoraria from GSK and Abbvie. JCH has received consulting fees from Alexion and speaker honoraria from Alexion, Pfizer and Gebro. DC has received grants or research support from AbbVie and Pfizer and speaker honoraria from Novartis, AbbVie, Roche, Pfizer, GSK and Sobi. JCNG has received grants or research support from Nordic Pharma; consulting fees from Galápagos, Abbvie, GSK, Janssen and MSD; and speaker honoraria from MSD, Pfizer, Abbvie, UCB Pharma, Janssen, Lilly, Roche, Nordic Pharma, Gebro, Novartis, Biogen, Amgen and Sandoz. CL and LL are employees from GSK. IC has received consulting fees from Mereo Byopharma, Amgen, Novartis, Sobi, GSK and Abbvie; and speaker honoraria from Pfizer, Abbvie, Novartis, Sobi, Mereo Byopharma and GSK.

Figures

Fig. 1
Fig. 1
Management of cSLE over the last two decades in Spain
Fig. 2
Fig. 2
Current unmet needs in cSLE management in Spain
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update Οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14–25. - PubMed
    1. Zucchi D, Elefante E, Schilirò D, Signorini V, Trentin F, Bortoluzzi A, et al. One year in review 2022: systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):4–14. - PubMed
    1. Chen F, Zheng Y, Chen X, Wen Z, Xu Y, Yang J, Xu K. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022;13:940416. - PMC - PubMed
    1. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–7. - PubMed
    1. Torrente-Segarra V, Salman Monte TC, Rúa-Figueroa I, Sánchez-Alonso F, López-Longo FJ, et al. Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish society of rheumatology lupus registry (RELESSER). Clin Exp Rheumatol. 2017;35(6):1047–55. - PubMed

MeSH terms

LinkOut - more resources